#### Edgar Filing: DOR BIOPHARMA INC - Form 4

DOR BIOPHARM	IA INC										
Form 4 November 15, 200	)4										
FORM 4									1B AI	PPROVA	۱L
	UNITED	STATES		RITIES A shington			COMMISSIO	N OMB Numbe	ər:	3235-	-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5				SECUE	RITIES		WNERSHIP OF	Estima burder respor	ated a	•	ry 31, 2005 0.5
obligations may continue. <i>See</i> Instruction 1(b).	-	a) of the I	Public U	Itility Hol	ding Con		of 1935 or Secti				
(Print or Type Respon	ses)										
1. Name and Address KESSEL LARRY		Person <u>*</u>	Symbol	er Name and		-	5. Relationship Issuer	of Reportin	g Per	son(s) to	
				BIOPHAR		[DOR]	(Che	eck all appl	icable	e)	
(Last) (F 1691 MICHIGAN	, ,	Middle) ITE 435		of Earliest Tr Day/Year) 2004	ransaction		X_ Director Officer (giv below)	ve title	Oth	6 Owner er (specify	
(s MIAMI, FL 3313	treet)			endment, Da onth/Day/Yea	-	I	6. Individual or Applicable Line) _X_ Form filed by Form filed by	y One Report	ing Pe	erson	
							Person				
(City) (S	tate)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Bene	ficial	lly Owne	d
	nsaction Date h/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownersl Form: Dire (D) or Indi (I) (Instr. 4)	ect	7. Nature Indirect Beneficia Ownersh (Instr. 4)	al iip
Reminder: Report on a	a separate line	for each cla	ass of sec	urities benef	ficially own	ed directly	or indirectly.				
					Perso inform requir	ns who res ation cont ed to resp ys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	S	SEC 1474 (9-02)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

#### Edgar Filing: DOR BIOPHARMA INC - Form 4

	Derivative Security				or Dispose (D) (Instr. 3, 4 and 5)					
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Options (right to buy)	\$ 0.47	11/10/2004	А		50,000		11/10/2004	11/10/2014	Common Stock	50,00
Stock Options (right to buy)	\$ 0.58						09/09/2004	11/10/2007 <u>(1)</u>	Common Stock	50,00
Stock Options (right to buy)	\$ 0.9						09/15/2003	11/10/2007 <u>(1)</u>	Common Stock	50,00
Stock Options (right to buy)	\$ 0.85						03/14/2003	11/10/2007 <u>(1)</u>	Common Stock	150,00
Stock Options (right to buy)	\$ 0.2						10/23/2002	11/10/2007 <u>(1)</u>	Common Stock	100,00
Stock Options (right to buy)	\$ 0.25						06/29/2002	11/10/2007(1)	Common Stock	50,00

## **Reporting Owners**

Reporting Owner Name / Add	ress	Relationsh		
	Director	10% Owner	Officer	Other
KESSEL LARRY 1691 MICHIGAN AVE SUITE 435 MIAMI, FL 33139	Х			
Signatures				
/s/ Lawrence Kessel	11/15/2004			
**Signature of Reporting Person	Date			

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The date the stock options are exercisable was reduced to 3 years from date of acceptance of resignation on November 10, 2004.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.